Latest Insider Transactions at Forma Therapeutics Holdings, Inc. (FMTX)
This section provides a real-time view of insider transactions for Forma Therapeutics Holdings, Inc. (FMTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Forma Therapeutics Holdings, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Forma Therapeutics Holdings, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 14
2022
|
Ra Capital Management, L.P. Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
9,018,901
-100.0%
|
-
|
|
Oct 14
2022
|
Timothy P Clackson Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
30,840
-100.0%
|
-
|
|
Oct 14
2022
|
Peter Wirth Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
134,915
-100.0%
|
-
|
|
Oct 14
2022
|
Thomas G Wiggans Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
7,250
-100.0%
|
-
|
|
Oct 14
2022
|
Todd Shegog SVP, Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
56,143
-100.0%
|
-
|
|
Oct 14
2022
|
John E Bishop SVP, Chief Technology Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
47,950
-100.0%
|
-
|
|
Oct 14
2022
|
Agustin Melian EVP, Research & Development |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
79,000
-100.0%
|
-
|
|
Oct 14
2022
|
Arturo Md Molina Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
10,000
-100.0%
|
-
|
|
Oct 14
2022
|
Frank D. Lee President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
201,436
-100.0%
|
-
|
|
Oct 14
2022
|
Wayne A.I. Frederick Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
7,250
-100.0%
|
-
|
|
Oct 14
2022
|
Marsha Fanucci Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
59,782
-100.0%
|
-
|
|
Oct 14
2022
|
Jeannette Potts Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
47,358
-100.0%
|
-
|
|
Oct 14
2022
|
Brian Andrew Lesser SVP, Commercial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
52,593
-100.0%
|
-
|
|
Jul 11
2022
|
Agustin Melian EVP, Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
79,000
+50.0%
|
-
|
|
Jun 08
2022
|
Arturo Md Molina Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+31.03%
|
-
|
|
Jun 08
2022
|
Marsha Fanucci Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+7.0%
|
-
|
|
Jun 08
2022
|
Timothy P Clackson Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+12.73%
|
-
|
|
Jun 08
2022
|
Peter Wirth Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+3.23%
|
-
|
|
Jun 08
2022
|
Thomas G Wiggans Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+38.3%
|
-
|
|
Jun 08
2022
|
Selwyn M Md Vickers Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+38.3%
|
-
|
|
Jun 08
2022
|
Wayne A.I. Frederick Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+38.3%
|
-
|
|
Jun 08
2022
|
Ra Capital Management, L.P. Director |
BUY
Grant, award, or other acquisition
|
Indirect |
4,500
+38.3%
|
-
|
|
Apr 08
2022
|
Patrick F. Kelly SVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.51%
|
$75,000
$5.05 P/Share
|
|
Feb 28
2022
|
Jeannette Potts Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+34.55%
|
-
|
|
Feb 28
2022
|
Brian Andrew Lesser SVP, Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+36.99%
|
-
|
|
Feb 28
2022
|
Todd Shegog SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,330
+37.25%
|
-
|
|
Feb 28
2022
|
Patrick F. Kelly SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+21.76%
|
-
|
|
Feb 28
2022
|
John E Bishop SVP, Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,950
+35.12%
|
-
|
|
Feb 28
2022
|
David N Cook SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+37.61%
|
-
|
|
Feb 28
2022
|
Frank D. Lee President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
121,667
+37.66%
|
-
|
|
Feb 23
2022
|
Jeannette Potts Officer |
SELL
Open market or private sale
|
Direct |
4,672
-17.28%
|
$42,048
$9.78 P/Share
|
|
Feb 23
2022
|
Mary E. Wadlinger Officer |
SELL
Open market or private sale
|
Direct |
4,684
-3.36%
|
$42,156
$9.78 P/Share
|
|
Feb 23
2022
|
Brian Andrew Lesser SVP, Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,837
-17.9%
|
$34,533
$9.78 P/Share
|
|
Feb 23
2022
|
Todd Shegog SVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,687
-19.95%
|
$51,183
$9.78 P/Share
|
|
Feb 23
2022
|
Patrick F. Kelly SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,245
-7.48%
|
$47,205
$9.78 P/Share
|
|
Feb 23
2022
|
Frank D. Lee President and CEO |
SELL
Open market or private sale
|
Direct |
17,981
-18.39%
|
$161,829
$9.78 P/Share
|
|
Feb 23
2022
|
David N Cook SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,531
-17.66%
|
$31,779
$9.78 P/Share
|
|
Jan 12
2022
|
Arturo Md Molina Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+50.0%
|
-
|
|
Jun 17
2021
|
Peter Kolchinsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,750
+50.0%
|
-
|
|
Jun 17
2021
|
Peter Wirth Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,750
+2.07%
|
-
|
|
Jun 17
2021
|
Marsha Fanucci Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,750
+4.74%
|
-
|
|
Jun 17
2021
|
Timothy P Clackson Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,750
+9.45%
|
-
|
|
Jun 17
2021
|
Thomas G Wiggans Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,750
+50.0%
|
-
|
|
Jun 17
2021
|
Wayne A.I. Frederick Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,750
+50.0%
|
-
|
|
Jun 17
2021
|
Selwyn M Md Vickers Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,750
+50.0%
|
-
|
|
Jun 14
2021
|
John E Bishop SVP, Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+50.0%
|
-
|
|
Apr 01
2021
|
Ra Capital Management, L.P. Director |
BUY
Other acquisition or disposition
|
Indirect |
542,018
+6.74%
|
$15,176,504
$28.02 P/Share
|
|
Feb 26
2021
|
Patrick F. Kelly SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,170
+39.1%
|
-
|
|
Feb 26
2021
|
Frank D. Lee President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
97,750
+39.52%
|
-
|
|
Feb 26
2021
|
Todd Shegog SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,500
+39.81%
|
-
|